Compare Super Micro Computer Inc (SMCI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Super Micro Computer Inc vs Summit Therapeutics Inc — how do they compare? Super Micro Computer Inc trades at $25.24 (market cap $15.41B), while Summit Therapeutics Inc trades at $14.41 (market cap $10.48B). The key difference: Super Micro Computer Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| SMCI | SMMT | |
|---|---|---|
Market Cap | $15.41B | $10.48B |
Sector | Technology | Health |
52-Week High | $60.71 | $29.32 |
52-Week Low | $20.53 | $13.05 |
Enterprise Value | $22.93B | $9.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Super Micro Computer (SMCI) trades at $23.83, down 1.41% on the day, with a bearish technical signal despite recent earnings beats. Valuation ratios appear attractive with a P/E of 12.73 and P/S of 0.48, but cash flow trends show strain with a projected negative net cash flow of $1.2B in 2026. The company is expanding its liquid cooling portfolio for AI data centers, but faces investor concerns over inventory growth and competitive pressures.
The outlook is mixed: strong AI demand and low valuations offer upside potential, but cash flow volatility, rising competition, and a Taiwan regulatory probe pose significant risks. Analyst consensus is cautious with a $36.71 price target, reflecting 54% upside, yet hold ratings dominate at 56% due to near-term execution challenges.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.
The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Super Micro Computer Inc
Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
